Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

被引：9

作者：

Jacobs, Kenneth ^{[1
]}

Viero, Cedric ^{[2
]}

Godwin, John ^{[3
]}

Baughman, Jan ^{[4
]}

Sun, Jichao ^{[1
]}

Ying, Kang ^{[1
]}

Muth, John ^{[1
]}

Hong, Shengyan ^{[1
]}

Vey, Norbert ^{[5
]}

Sweet, Kendra L. ^{[6
]}

Uy, Geoffrey L. ^{[7
]}

Ravandi, Farhad ^{[8
]}

Foster, Matthew C. ^{[9
]}

Rizzieri, David A. ^{[10
]}

Arellano, Martha L. ^{[11
]}

Rettig, Michael P. ^{[12
]}

Topp, Max S. ^{[13
]}

Huls, Gerwin ^{[14
]}

Lelievre, Helene ^{[2
]}

Paolini, Stefania ^{[15
]}

Ciceri, Fabio ^{[16
]}

Carrabba, Matteo Giovanni ^{[17
]}

Lowenberg, Bob ^{[18
]}

DiPersio, John F. ^{[12
]}

Wigginton, Jon ^{[1
]}

Davidson-Moncada, Jan K. ^{[19
]}

机构：

[1] MacroGenics Inc, Rockville, MD USA

[2] Servier, Paris, France

[3] Providence Portland Med Ctr, Portland, OR USA

[4] MacroGenics Inc, San Francisco, CA USA

[5] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[6] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[10] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA

[13] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[14] Univ Med Ctr Groningen, Hematol, Groningen, Netherlands

[15] Univ Bologna, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[16] Ist Sci San Raffaele, Hematol & Bone Marrow Transplantat Unit, Milan, Italy

[17] IRCCS San Raffaele Sci Inst, Hematol & Bone Marrow Transplantat Unit, Milan, Italy

[18] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands

[19] MacroGenics Inc, Washington, DC USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112615

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2738

引用

页数：4

共 50 条

[41] Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells
Krupka, Christina
Brauneck, Franziska
Lichtenegger, Felix S.
Kufer, Peter
Kischel, Roman
Zugmaier, Gerhard
Khnke, Thomas
Altmann, Torben
Schneider, Stephanie
Fiegl, Michael
Spiekermann, Karsten
Sinclair, Angus M.
Newhall, Kathryn J.
Frankel, Stanley R.
Baeuerle, Patrick
Hiddemann, Wolfgang
Riethmueller, Gert
Subklewe, Marion
BLOOD, 2014, 124 (21)
[42] T cell engager (TCE) score in patients treated with bispecific CD3 TCE in phase I clinical trials
Herbel, Noe
Goldschmidt, Vincent
Michot, Jean-Marie
Laparra, Ariane
Geraud, Arthur
Ouali, Kaissa
Danlos, Francois-Xavier
Vuagnat, Perrine
Bernard-Tessier, Alice
Gazzah, Anas
Bahleda, Rastilav
Hollebecque, Antoine
Marabelle, Aurelien
Postel-Vinay, Sophie
Loriot, Yohann
Massard, Christophe
Ribrag, Vincent
Aix, Santiago Ponce
Champiat, Stephane
Baldini, Capucine
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
Laszlo, George S.
Gudgeon, Chelsea J.
Harrington, Kimberly H.
Dell'Aringa, Justine
Newhall, Kathryn J.
Means, Gary D.
Sinclair, Angus M.
Kischel, Roman
Frankel, Stanley R.
Walter, Roland B.
BLOOD, 2014, 123 (04) : 554 - 561
[44] Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
de Zafra, Christina L. Zuch
Fajardo, Flordeliza
Zhong, Wendy
Bernett, Matthew J.
Muchhal, Umesh S.
Moore, Gregory L.
Stevens, Jennitte
Case, Ryan
Pearson, Joshua T.
Liu, Siyuan
McElroy, Patricia L.
Canon, Jude
Desjarlais, John R.
Coxon, Angela
Balazs, Mercedesz
Nolan-Stevaux, Olivier
CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3921 - 3933
[45] Mesothelin/CD3 Half-Life-Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues
Suurs, Frans, V
Lorenczewski, Grit
Bailis, Julie M.
Stienen, Sabine
Friedrich, Matthias
Lee, Fei
van der Vegt, Bert
de Vries, Elisabeth G. E.
de Groot, Derk-Jan A.
Lub-de Hooge, Marjolijn N.
JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (12) : 1797 - 1804
[46] CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy
Humbert, Olivier
Llewellyn, Mallory J.
Laszlo, George S.
Walter, Roland B.
Kiem, Hans-Peter
BLOOD, 2019, 134
[47] Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
Juluri, Krishna R.
Wu, Qian Vicky
Voutsinas, Jenna
Hou, Jue
Hirayama, Alexandre, V
Mullane, Erin
Miles, Nancy
Maloney, David G.
Turtle, Cameron J.
Bar, Merav
Gauthier, Jordan
BLOOD ADVANCES, 2022, 6 (07) : 2055 - 2068
[48] A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
Naguyen, Daniel
Ravandi, Farhad
Wang, Sa A.
Jorgensen, Jeffrey L.
Wang, Wei
Chien, Kelly S.
Montalban-Bravo, Guillermo
Issa, Ghayas C.
Maiti, Abhishek
Valero, Yesid Alvarado
Daver, Naval
DiNardo, Courtney D.
Jabbour, Elias
Kadia, Tapan M.
Pemmaraju, Naveen
Yilmaz, Musa
Lee, Jaehyun
Bachireddy, Pavan
Popat, Uday R.
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Short, Nicholas J.
BLOOD, 2023, 142
[49] A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure
Short, Nicholas James
Bachireddy, Pavan
Huang, Xuelin
Hwang, Hyunsoo
Leng, Xiaohong
Lee, Jaehyun
Nguyen, Danielle
Garcia-Manero, Guillermo
Dinardo, Courtney Denton
Borthakur, Gautam
Kadia, Tapan M.
Daver, Naval Guastad
Issa, Ghayas C.
Maiti, Abhishek
Ravandi, Farhad
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] DISCORDANT EXPRESSION OF CD3 AND T-CELL RECEPTOR ANTIGENS ON LYMPHOCYTES FROM PATIENTS TREATED WITH OKT3
GEBEL, HM
LEBECK, LL
JENSIK, SC
LANDAY, AL
BRAY, RA
TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 1745 - 1746

← 1 2 3 4 5 →